Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03006926 · ClinicalTrials.gov registry record · Phase 1
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
A Phase 1 study, sponsored by Eisai Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT03006926 is a Phase 1 study that has completed, run by Eisai Co.. The registered enrollment target is 104 participants.
The verdict
NCT03006926, a Phase 1 study, has completed, sponsored by Eisai Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC). The study will evaluate objective response rate and duration of response by modified Response Evaluation Criteria In Solid Tumors (mRECIST) for HCC and Response Evaluation Criteria In Solid Tumors (RECIST 1.1) based on independent imaging review (IIR).
Interventions
- DRUG lenvatinib
- DRUG pembrolizumab (200 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2017-02-13 |
| Est. Completion | 2022-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03006926
The ClinicalTrials.gov registry entry for NCT03006926 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai Co., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which lenvatinib is the first listed.
NCT03006926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03006926 about?
NCT03006926 is a clinical study titled "A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma". This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC). The study will evaluate objective response rate and duration of response by modified Response Evaluation Criteria...
What is the current status of trial NCT03006926?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2017-02-13. Estimated completion is 2022-11-22.
What interventions are being tested in trial NCT03006926?
The interventions under investigation include: lenvatinib (DRUG), pembrolizumab (200 mg) (DRUG).
Who is sponsoring clinical trial NCT03006926?
This trial is sponsored by Eisai Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.